PharmaGraphX

Log in Get Started

Lenvatinib

Lenvima

Tyrosine kinase inhibitor

Standard

Half-life

28 hours

Protein Binding

98-99%

Metabolized By

N/A

External

Drugs.com

Clinical alerts

Bleeding risk

Additive with other antithrombotics and NSAIDs

QT prolongation

Avoid combining with other QT-prolonging agents; check electrolytes

Nephrotoxic

Monitor renal function; avoid other nephrotoxins where possible

Hepatotoxic

Monitor liver function

Mechanism of action

Inhibits VEGFR1-3, FGFR1-4, PDGFRa, RET, KIT

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Vulva Cancer
·Salivary Gland Carcinoma
·Precision Therapy
·Differentiated Thyroid Cancer
·Resectable Hepatocellular Carcinoma

Interactions

No curated interaction pairs are recorded for Lenvatinib. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Hypertension
Fatigue
Diarrhea
Proteinuria
Decreased appetite

Food, alcohol & herbal

Alcohol · moderate

Additive hepatotoxicity

Pharmacokinetics

Half-life: 28 hours
Protein binding: 98-99%
Metabolised by: CYP3A4

Pregnancy & lactation

Not recorded for Lenvatinib. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database.

Not a substitute for clinical judgement